Eric Warren

CIK: 0001916048

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)12 (70.6%)

Position reduction

Option Exercises (M)4 (23.5%)

Derivative conversions

Awards (A)1 (5.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

MLYS

Mineralys Therapeutics, Inc.

Officer

ESPR

Esperion Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

MLYS
Mineralys Therapeutics, Inc.
Sep 21, 2026
Exercise(M)
Direct
7.4K shares at avg. $13.24$98K
MLYS
Mineralys Therapeutics, Inc.
Sep 21, 2026
Sale(S)
Direct
7.4K shares at avg. $28.12$209K
MLYS
Mineralys Therapeutics, Inc.
Aug 21, 2026
Exercise(M)
Direct
7.4K shares at avg. $13.24$98K
MLYS
Mineralys Therapeutics, Inc.
Aug 21, 2026
Sale(S)
Direct
7.4K shares at avg. $25.98$193K
MLYS
Mineralys Therapeutics, Inc.
Jul 21, 2026
Sale(S)
Direct
7.4K shares at avg. $26.87$200K
MLYS
Mineralys Therapeutics, Inc.
Jul 21, 2026
Exercise(M)
Direct
7.4K shares at avg. $13.24$98K
MLYS
Mineralys Therapeutics, Inc.
Jun 26, 2026
Exercise(M)
Direct
104.1K shares at avg. $13.24$1.4M
MLYS
Mineralys Therapeutics, Inc.
Jun 26, 2026
Sale(S)
Direct
104.1K shares at avg. $25.90$2.7M
ESPR
Esperion Therapeutics, Inc.
Apr 17, 2025
Sale(S)
Direct
108 shares at avg. $0.98$105.624
ESPR
Esperion Therapeutics, Inc.
Mar 18, 2025
Sale(S)
Direct
2.4K shares at avg. $1.49$4K
ESPR
Esperion Therapeutics, Inc.
Mar 14, 2025
Award(A)
Direct
213K shares-
ESPR
Esperion Therapeutics, Inc.
Feb 19, 2025
Sale(S)
Direct
239 shares at avg. $1.87$446.452
ESPR
Esperion Therapeutics, Inc.
Jan 17, 2025
Sale(S)
Direct
123 shares at avg. $2.26$277.98
ESPR
Esperion Therapeutics, Inc.
Dec 17, 2024
Sale(S)
Direct
2.2K shares at avg. $2.43$5K
ESPR
Esperion Therapeutics, Inc.
Nov 19, 2024
Sale(S)
Direct
197 shares at avg. $2.17$426.505
ESPR
Esperion Therapeutics, Inc.
Oct 17, 2024
Sale(S)
Direct
107 shares at avg. $2.12$226.733
ESPR
Esperion Therapeutics, Inc.
Sep 17, 2024
Sale(S)
Direct
2.6K shares at avg. $1.78$5K

		Type	Shares	Price		Ownership
Sep 21, 2026	MLYS Mineralys Therapeutics, Inc.	Exercise(M)	7,438	$13.24	$98,479	Direct
Sep 21, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	7,438	$28.12	$209,136	Direct
Aug 21, 2026	MLYS Mineralys Therapeutics, Inc.	Exercise(M)	7,437	$13.24	$98,466	Direct
Aug 21, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	7,437	$25.98	$193,189	Direct
Jul 21, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	7,438	$26.87	$199,885	Direct
Jul 21, 2026	MLYS Mineralys Therapeutics, Inc.	Exercise(M)	7,438	$13.24	$98,479	Direct
Jun 26, 2026	MLYS Mineralys Therapeutics, Inc.	Exercise(M)	104,124	$13.24	$1,378,602	Direct
Jun 26, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	104,124	$25.90	$2,696,322	Direct
Apr 17, 2025	ESPR Esperion Therapeutics, Inc.	Sale(S)	108	$0.98	$106	Direct
Mar 18, 2025	ESPR Esperion Therapeutics, Inc.	Sale(S)	2,433	$1.49	$3,618	Direct
Mar 14, 2025	ESPR Esperion Therapeutics, Inc.	Award(A)	213,000	-	-	Direct
Feb 19, 2025	ESPR Esperion Therapeutics, Inc.	Sale(S)	239	$1.87	$446	Direct
Jan 17, 2025	ESPR Esperion Therapeutics, Inc.	Sale(S)	123	$2.26	$278	Direct
Dec 17, 2024	ESPR Esperion Therapeutics, Inc.	Sale(S)	2,234	$2.43	$5,426	Direct
Nov 19, 2024	ESPR Esperion Therapeutics, Inc.	Sale(S)	197	$2.17	$427	Direct
Oct 17, 2024	ESPR Esperion Therapeutics, Inc.	Sale(S)	107	$2.12	$227	Direct
Sep 17, 2024	ESPR Esperion Therapeutics, Inc.	Sale(S)	2,608	$1.78	$4,650	Direct

1-17 of 17 transactions

About Warren Eric

Warren Eric (SEC CIK 0001916048) files insider reports with the SEC as Chief Commercial Officer of Mineralys Therapeutics, Inc. (MLYS) and Chief Commercial Officer of Esperion Therapeutics, Inc. (ESPR).

Signal8 holds 14 ownership filings by Warren Eric (1 Form 3, 13 Form 4), filed between Sep 18, 2024 and Sep 22, 2026. Those filings report 17 transactions, from Sep 17, 2024 to Sep 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Warren Eric's filings is in RADNOR, PA.

Recent filings by Warren Eric

Sep 21, 2026: Option exercise of MLYS shares (Form 4, code M).
Sep 21, 2026: Open-market sale of MLYS shares (Form 4, code S).
Aug 21, 2026: Option exercise of MLYS shares (Form 4, code M).
Aug 21, 2026: Open-market sale of MLYS shares (Form 4, code S).
Jul 21, 2026: Open-market sale of MLYS shares (Form 4, code S).

Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)

Peterson Kristine, Director
COATS LONNEL, Director
Congleton Jon, Chief Executive Officer
Slingsby Brian Taylor, Director
Karydas Daphne, Director
Ferguson James J. III, Chief Medical Officer

How to read Form 4 transaction codes